Using Carboplatin to Treat Fluid Buildup in Lung Cancer Patients
Author Information
Author(s): Moriya T, Takiguchi Y, Tabeta H, Watanabe R, Kimura H, Nagao K, Kuriyama T
Primary Institution: Chiba University School of Medicine
Hypothesis
Can intrapericardial administration of carboplatin effectively control malignant pericardial effusions in patients with non-small-cell lung cancer?
Conclusion
Intrapericardial administration of carboplatin effectively controlled malignant pericardial effusions in most patients without major side effects.
Supporting Evidence
- Nine out of ten patients showed satisfactory results.
- Eight patients experienced complete regression of the effusion.
- No major or minor adverse effects were observed.
Takeaway
Doctors gave a special medicine called carboplatin directly into the heart area of 10 lung cancer patients to help with fluid buildup, and it worked really well for most of them.
Methodology
The study involved draining the pericardial effusion and infusing 300 mg of carboplatin in saline into the pericardial space.
Participant Demographics
Patients with primary non-small-cell lung cancer experiencing malignant pericardial effusion.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website